Tuberculosis: from genome to vaccine

References

• Donoghue HD, Spigelman M, Greenblatt CL et al. Tuberculosis: from prehistory to Robert Koch, as revealed by ancient DNA. Lancet Infect. Dis.4(9), 584–592 (2004).
   PubMed Web of Science ®Google Scholar
• Raviglione MC. The TB epidemic from 1992 to 2002. Tuberculosis 83(1–3), 4–14 (2003).
   PubMed Web of Science ®Google Scholar
• Comstock GW Epidemiology of tuberculosis. Am. Rev. Respir. Dis. 125(Suppl.), 8–16 (1982).
   PubMed Web of Science ®Google Scholar
• Mitchison DA. The diagnosis and therapy of tuberculosis during the past 100 years. Am. J. Respir. Crit. Care Med. 171(7), 699–706 (2005).
   PubMed Web of Science ®Google Scholar
• Andries K, Verhasselt P, Guillemont J et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307(5707), 223–227 (2005).
   PubMed Web of Science ®Google Scholar
• Brennan MJ The tuberculosis vaccine challenge. Tuberculosis 85(1–2), 7–12 (2005).
   PubMed Web of Science ®Google Scholar
• Cole ST, Brosch R, Parkhill J et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393(6685), 537–544 (1998).
   PubMed Web of Science ®Google Scholar
• Fleischmann RD, Alland D, Eisen JA et al. Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J. Bacteriol. 184(19), 5479–5490 (2002).
   PubMed Web of Science ®Google Scholar
• Valway SE, Sanchez MP, Shinnick TF et al. An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis. N. Engl. J. Med. 338(10), 633–639 (1998).
   PubMed Web of Science ®Google Scholar
• Betts JC, Dodson P, Quan S et al. Comparison of the proteome of Mycobacterium tuberculosis strain H37Rv with clinical isolate CDC 1551. Microbiology146(Pt.12), 3205–3216 (2000).
   PubMedGoogle Scholar
• Manca C, Tsenova L, Barry CE 3rd et al. Mycobacterium tuberculosis CDC1551 induces a more vigorous host response in vivo and in vitro, but is not more virulent than other clinical isolates. J. Immunol. 162(11), 6740–6746 (1999).
   PubMed Web of Science ®Google Scholar
• Bishai WR, Dannenberg AM Jr, Parrish N et al. Virulence of Mycobacterium tuberculosis CDC1551 and H37Rv in rabbits evaluated by Lurie's pulmonary tubercle count method. Infect. Immunol. 67(9), 4931–4934 (1999).
   PubMed Web of Science ®Google Scholar
• Manca C, Reed MB, Freeman S et al. Differential monocyte activation underlies strain–specific Mycobacterium tuberculosis pathogenesis. Infect. Immunol. 72(9), 5511–5514 (2004).
   PubMed Web of Science ®Google Scholar
• Ramakrishnan L, Federspiel NA, Falkow S. Granuloma-specific expression of Mycobacterium virulence proteins from the glycine-rich PE-PGRS family. Science 288(5470), 1436–1439 (2000).
   PubMed Web of Science ®Google Scholar
• Skeiky YA, Ovendale PJ, Jen S et al. T-cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection. J. Immunol.165(12), 7140–7149 (2000).
   Google Scholar
• Banu S, Honore N, Saint-Joanis B, Philpott D, Prevost MC, Cole ST. Are the PE-PGRS proteins of Mycobacterium tuberculosis variable surface antigens? Mol. Microbiol. 44(1), 9–19 (2002).
   PubMed Web of Science ®Google Scholar
• Voskuil MI, Schnappinger D, Rutherford R, Liu Y, Schoolnik GK Regulation of the Mycobacterium tuberculosis PE/PPE genes. Tuberculosis 84(3–4), 256–262 (2004).
   PubMedGoogle Scholar
• Raynaud C, Guilhot C, Rauzier J et al. Phospholipases C are involved in the virulence of Mycobacterium tuberculosis. Mol. Microbiol. 45(1), 203–217 (2002).
   PubMed Web of Science ®Google Scholar
• Reed MB, Domenech P, Manca C et al. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature 431(7004), 84–87 (2004).
   PubMed Web of Science ®Google Scholar
• Hirsh AE, Tsolaki AG, DeRiemer K, Feldman MW, Small PM. Stable association between strains of Mycobacterium tuberculosis and their human host populations. Proc. Natl Acad. Sci. USA 101(14), 4871–4876 (2004).
   PubMedGoogle Scholar
• Tsolaki AG, Hirsh AE, DeRiemer K et al. Functional and evolutionary genomics of Mycobacterium tuberculosis: insights from genomic deletions in 100 strains. Proc. Natl Acad. Sci. USA 101(14), 4865–4870 (2004).
   Google Scholar
• Malik AN, Godfrey-Faussett P. Effects of genetic variability of Mycobacterium tuberculosis strains on the presentation of disease. Lancet Infect. Dis. 5(3), 174–183 (2005).
   PubMed Web of Science ®Google Scholar
• Cole ST, Eiglmeier K, Parkhill J et al. Massive gene decay in the leprosy bacillus. Nature 409(6823), 1007–1011 (2001).
   PubMed Web of Science ®Google Scholar
• Philipp WJ, Schwartz DC, Telenti A, Cole ST. Mycobacterial genome structure. Electrophoresis 19(4), 573–576 (1998).
   PubMedGoogle Scholar
• Brosch R, Gordon SV, Eiglmeier K, Garnier T, Cole ST. Comparative genomics of the leprosy and tubercle bacilli. Res. Microbiol.151(2), 135–142 (2000).
   PubMedGoogle Scholar
• Noordeen SK. The epidemiology of leprosy. In: Leprosy (2nd Edition), RC Hastings (Ed.), Churchill–Livingstone, Edinburgh, UK, 29–48 (1994).
   Google Scholar
• Schorey JS, Carroll MC, Brown EJ. A macrophage invasion mechanism of pathogenic mycobacteria. Science 277(5329), 1091–1093 (1997).
   PubMedGoogle Scholar
• Marmiesse M, Brodin P, Buchrieser C et al. Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex. Microbiology 150(Pt. 2), 483–496 (2004).
   PubMed Web of Science ®Google Scholar
• Gormus BJ, Meyers WM. Under-explored experimental topics related to integral mycobacterial vaccines for leprosy. Expert Rev. Vaccines 2(6), 791–804 (2003).
   PubMedGoogle Scholar
• Calmette A. La Vaccination Preventive Contre la Tuberculose, Masson et Cie, Paris, France (1927).
   Google Scholar
• Mahairas GG, Sabo PJ, Hickey MJ, Singh DC, Stover CK. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J. Bacteriol.178(5),1274–1282 (1996).
   PubMed Web of Science ®Google Scholar
• Behr MA, Wilson MA, Gill WP et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284(5419), 1520–1523 (1999).
   Google Scholar
• Gordon SV, Brosch R, Billault A, Garnier T, Eiglmeier K, Cole ST. Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays. Mol. Microbiol.32(3), 643–655 (1999).
   PubMed Web of Science ®Google Scholar
• Brosch R, Gordon SV, Buchrieser C, Pym AS, Garnier T, Cole ST. Comparative genomics uncovers large tandem chromosomal duplications in Mycobacterium bovis BCG Pasteur. Yeast 17(2), 111–123 (2000).
   PubMed Web of Science ®Google Scholar
• Garnier T, Eiglmeier K, Camus JC et al. The complete genome sequence of Mycobacterium bovis. Proc. Natl Acad. Sci. USA100(13), 7877–7882 (2003).
   PubMed Web of Science ®Google Scholar
• Pym AS, Brodin P, Brosch R, Huerre M, Cole ST. Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol Microbiol. 46(3), 709–717 (2002).
   PubMed Web of Science ®Google Scholar
• Pym AS, Brodin P, Majlessi L et al. Recombinant BCG exporting ESAT–6 confers enhanced protection against tuberculosis. Nature Med.9(5), 533–539 (2003).
   PubMed Web of Science ®Google Scholar
• Claros MG, von Heijne G. TopPred II: an improved software for membrane protein structure predictions. Comput. Appl. Biosci. 10(6), 685–686 (1994).
   PubMedGoogle Scholar
• Nielsen H, Engelbrecht J, Brunak S, von Heijne G. Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. Protein Eng.10(1), 1–6 (1997).
   PubMedGoogle Scholar
• De Groot AS, Bosma A, Chinai N et al. From genome to vaccine: in silico predictions, ex vivo verification. Vaccine 19(31), 4385–4395 (2001).
   PubMedGoogle Scholar
• Chaitra MG, Hariharaputran S, Chandra NR, Shaila MS, Nayak R. Defining putative T-cell epitopes from PE and PPE families of proteins of Mycobacterium tuberculosis with vaccine potential.Vaccine 23(10), 1265–1272 (2005).
   PubMed Web of Science ®Google Scholar
• De Groot AS, McMurry J, Marcon L et al. Developing an epitope-driven tuberculosis (TB) vaccine. Vaccine 23(17–18), 2121–2131 (2005).
   PubMedGoogle Scholar
• Flyer DC, Ramakrishna V, Miller C et al. Identification by mass spectrometry of CD8(+)-T-cell Mycobacterium tuberculosis epitopes within the Rv0341 gene product. Infect. Immunol. 70(6), 2926–2932 (2002).
   PubMedGoogle Scholar
• Mostowy S, Cleto C, Sherman DR, Behr MA. The Mycobacterium tuberculosis complex transcriptome of attenuation. Tuberculosis84(3–4), 197–204 (2004).
   PubMed Web of Science ®Google Scholar
• Sun R, Converse PJ, Ko C, Tyagi S, Morrison NE, Bishai WR. Mycobacterium tuberculosis ECF sigma factor sigC is required for lethality in mice and for the conditional expression of a defined gene set. Mol. Microbiol. 52(1), 25–38 (2004).
   PubMedGoogle Scholar
• Schnappinger D, Ehrt S, Voskuil MI et al. Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: insights into the phagosomal environment. J. Exp. Med.198(5), 693–704 (2003).
   PubMed Web of Science ®Google Scholar
• Mattow J, Jungblut PR, Schaible UE et al. Identification of proteins from Mycobacterium tuberculosis missing in attenuated Mycobacterium bovis BCG strains. Electrophoresis22(14), 2936–2946 (2001).
   PubMedGoogle Scholar
• Starck J, Kallenius G, Marklund BI, Andersson DI, Akerlund T. Comparative proteome analysis of Mycobacterium tuberculosis grown under aerobic and anaerobic conditions. Microbiology 150(Pt. 11), 3821–3829 (2004).
   Google Scholar
• Andersen P, Askgaard D, Ljungqvist L, Bennedsen J, Heron I. Proteins released from Mycobacterium tuberculosis during growth. Infect. Immun.59(6), 1905–1910 (1991).
   PubMed Web of Science ®Google Scholar
• Orme IM, Roberts AD, Griffin JP, Abrams JS. Cytokine secretion by CD4 T lymphocytes acquired in response to Mycobacterium tuberculosis infection. J. Immunol. 151(1), 518–525 (1993).
   Google Scholar
• Mattow J, Schaible UE, Schmidt F. Comparative proteome analysis of culture supernatant proteins from virulent Mycobacterium tuberculosis H37Rv and attenuated M. bovis BCG Copenhagen. Electrophoresis 24(19–20), 3405–3420 (2003).
   PubMed Web of Science ®Google Scholar
• Pethe K, Alonso S, Biet F et al. The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. Nature412(6843), 190–194 (2001).
   PubMedGoogle Scholar
• Temmerman S, Pethe K, Parra M et al. Methylation-dependent T-cell immunity to Mycobacterium tuberculosis heparin-binding hemagglutinin. Nature Med. 10(9), 935–941 (2004).
   PubMed Web of Science ®Google Scholar
• Rosat JP, Grant EP, Beckman EM et al. CD1-restricted microbial lipid antigen-specific recognition found in the CD8+ αβ T-cell pool. J. Immunol.162(1), 366–371 (1999).
   PubMedGoogle Scholar
• Moody DB, Ulrichs T, Muhlecker W et al. CD1c-mediated T-cell recognition of isoprenoid glycolipids in Mycobacterium tuberculosis infection. Nature 404(6780), 884–888 (2000).
   PubMed Web of Science ®Google Scholar
• Gilleron M, Stenger S, Mazorra Z Diacylated sulfoglycolipids are novel mycobacterial antigens stimulating CD1-restricted T-cells during infection with Mycobacterium tuberculosis. J. Exp. Med.199(5), 649–659 (2004).
   PubMed Web of Science ®Google Scholar
• Flynn JL. Immunology of tuberculosis and implications in vaccine development. Tuberculosis84(1–2), 93–101 (2004).
   PubMed Web of Science ®Google Scholar
• Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N. Engl. J. Med.340(5), 367–373 (1999).
   PubMed Web of Science ®Google Scholar
• Srikantiah P, Charlebois E, Havlir DV. Rapid increase in tuberculosis incidence soon after infection with HIV – a new twist in the twin epidemics. J. Infect. Dis. 191(2), 147–149 (2005).
   PubMedGoogle Scholar
• Turner J, D'Souza CD, Pearl JE et al. CD8- and CD95/95L-dependent mechanisms of resistance in mice with chronic pulmonary tuberculosis. Am. J. Respir. Cell. Mol. Biol.24(2), 203–209 (2001).
   PubMed Web of Science ®Google Scholar
• Behar SM, Dascher CC, Grusby MJ, Wang CR, Brenner MB. Susceptibility of mice deficient in CD1D or TAP1 to infection with Mycobacterium tuberculosis. J. Exp. Med. 189(12), 1973–1980 (1999).
   PubMed Web of Science ®Google Scholar
• Rolph MS, Raupach B, Kobernick HH. MHC class Ia-restricted T-cells partially account for β2-microglobulin-dependent resistance to Mycobacterium tuberculosis. Eur. J. Immunol.31(6), 1944–1949 (2001).
   PubMed Web of Science ®Google Scholar
• Stenger S, Hanson DA, Teitelbaum R et al. An antimicrobial activity of cytolytic T-cells mediated by granulysin. Science 282(5386), 121–125 (1998).
   PubMed Web of Science ®Google Scholar
• Cho S, Mehra V, Thoma-Uszynski S et al. Antimicrobial activity of MHC class I-restricted CD8+ T-cells in human tuberculosis. Proc. Natl Acad. Sci. USA 97(22), 12210–12215 (2000).
   PubMed Web of Science ®Google Scholar
• Waddell RD, Chintu C, Lein AD et al. Safety and immunogenicity of a five-dose series of inactivated Mycobacterium vaccae vaccination for the prevention of HIV-associated tuberculosis. Clin. Infect. Dis. 3(Suppl.), S309–S315 (2000).
   Google Scholar
• Vuola JM, Ristola MA, Cole B et al. Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial. AIDS17(16), 2351–2355 (2003).
   PubMedGoogle Scholar
• Sula L, Radkovsky I. Protective effects of M. microti vaccine against tuberculosis. J. Hyg. Epidemiol. Microbiol. Immunol.20(1), 1–6 (1976).
   PubMedGoogle Scholar
• Hart PD, Sutherland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Br. Med. J. 2(6082), 293–295 (1977).
   PubMed Web of Science ®Google Scholar
• Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon γ gene-disrupted mice. J. Exp. Med.178(6), 2243–2247 (1993).
   PubMed Web of Science ®Google Scholar
• Cooper AM, Roberts AD, Rhoades ER, Callahan JE, Getzy DM, Orme IM. The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection. Immunology84(3), 423–432 (1995).
   PubMed Web of Science ®Google Scholar
• Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J. Immunol.155(5), 2515–2524 (1995).
   Google Scholar
• Flynn JL, Goldstein MM, Triebold KJ, Sypek J, Wolf S, Bloom BR. The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection. Immunology84(3), 423–432 (1995).
   PubMedGoogle Scholar
• Altare F, Durandy A, Lammas D et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 280(5368), 1432–1435 (1998).
   PubMed Web of Science ®Google Scholar
• de Jong R, Altare F, Haagen IA et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 280(5368), 1435–1438 (1998).
   PubMedGoogle Scholar
• Dorman E and Holland SM. Mutation in the signal-transducing chain of the interferon-receptor and susceptibility to mycobacterial infection. J. Clin. Invest. 101, 2364–2369 (1998).
   PubMed Web of Science ®Google Scholar
• Montali RJ, Mikota SK, Cheng LI. Mycobacterium tuberculosis in zoo and wildlife species. Rev. Sci. Tech. 20(1), 291–303 (2001).
   PubMed Web of Science ®Google Scholar
• Flynn JL, Capuano SV, Croix D et al. Non-human primates: a model for tuberculosis research. Tuberculosis 83(1–3), 116–118 (2003).
   PubMed Web of Science ®Google Scholar
• McShane H, Pathan AA, Sander CR et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nature Med. 10(11), 1240–1244 (2004).
   PubMed Web of Science ®Google Scholar
• Doherty TM New vaccine against tuberculosis. Trop. Med. Int. Health 9(7), 818–826 (2004).
   PubMedGoogle Scholar
• Brandt L, Skeiky YA, Alderson MR et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect. Immun.72(11), 6622–6632 (2004).
   PubMed Web of Science ®Google Scholar
• Bosch X Tuberculosis vaccine trial gets underway. Lancet Infect. Dis. 4, 598 (2004).
   Google Scholar
• Brandt L, Feino Cunha J, Weinreieh Olsen A et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect. Immun. 70(2), 627–678 (2002).
   Google Scholar
• Black GF, Weir RE, Floyd S et al. BCG-induced increase in interferon-γ response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet 359(9315), 1393–1401 (2002).
   PubMed Web of Science ®Google Scholar
• De Lisle GW, Wards BJ, Buddle BM, Collins DM. The efficacy of live tuberculosis vaccines after presensitization with Mycobacterium avium. Tuberculosis85(1–2), 73–79 (2005).
   PubMedGoogle Scholar
• Demangel C, Garnier T, Rosenkrands I, Cole ST. Differential effects of prior exposure to environmental mycobacteria on vaccination with Mycobacterium bovis BCG or a recombinant BCG strain expressing RD1 antigens. Infect. Immun.73(4), 2190–196 (2005).
   PubMed Web of Science ®Google Scholar
• Sørensen AL, Nagai S, Houen G, Andersen P, Andersen AB. Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infect Immun. 63(5), 1710–1717 (1995).
   PubMed Web of Science ®Google Scholar
• Stanley SA, Raghavan S, Hwang WW, Cox JS. Acute infection and macrophage subversion by Mycobacterium tuberculosis require a specialized secretion system. Proc. Natl Acad. Sci. USA100(22), 13001–13006 (2003).
   PubMed Web of Science ®Google Scholar
• Majlessi L, Brodin P, Brosch R et al. Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. J. Immunol. 174(6), 3570–3579 (2005).
   PubMed Web of Science ®Google Scholar
• McShane H. Developing an improved vaccine against tuberculosis. Expert Rev. Vaccines 3(3), 299–306 (2004).
   PubMedGoogle Scholar
• Orme IM Current progress in tuberculosis vaccine development. Vaccine 23(17–18), 2105–2108 (2005).
   PubMed Web of Science ®Google Scholar
• Brosch R, Gordon SV, Marmiesse M et al. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc. Natl Acad. Sci. USA 99(6), 3684–3689 (2002).
   PubMed Web of Science ®Google Scholar
• McAdam RA, Weisbrod TR, Martin J et al. In vivo growth characteristics of leucine and methionine auxotrophic mutants of Mycobacterium bovis BCG generated by transposon mutagenesis. Infect. Immun. 63(3), 1004–1012 (1995).
   PubMed Web of Science ®Google Scholar
• Guleria I, Teitelbaum R, McAdam RA, Kalpana G, Jacobs WR Jr, Bloom BR. Auxotrophic vaccines for tuberculosis. Nature Med.2(3), 334–337 (1996).
   PubMed Web of Science ®Google Scholar
• Camacho LR, Ensergueix D, Perez E, Gicquel B, Guilhot C. Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis. Mol. Microbiol. 34(2), 257–267 (1999).
   PubMed Web of Science ®Google Scholar
• Sassetti CM, Boyd DH, Rubin EJ. Comprehensive identification of conditionally essential genes in mycobacteria.Proc. Natl Acad. Sci. USA 2001 98(22), 12712–12717 (2001).
   PubMed Web of Science ®Google Scholar
• Pavelka MS Jr, Chen B, Kelley CL, Collins FM, Jacobs WR Jr. Vaccine efficacy of a lysine auxotroph of Mycobacterium tuberculosis. Infect. Immun.71(7), 4190–4192 (2003).
   PubMed Web of Science ®Google Scholar
• Sambandamurthy VK, Wang X, Chen B et al. A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nature Med. 8(10), 1171–1174 (2002).
   PubMed Web of Science ®Google Scholar
• Sassetti CM, Rubin EJ Genetic requirements for mycobacterial survival during infection. Proc. Natl Acad. Sci. USA 100(22), 12989–12994 (2003).
   PubMed Web of Science ®Google Scholar
• Cox JS, Chen B, McNeil M, Jacobs WR Jr. Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice. Nature402(6757), 79–83 (1999).
   PubMed Web of Science ®Google Scholar
• Perez E, Samper S, Bordas Y, Guilhot C, Gicquel B, Martin C. An essential role for phoP in Mycobacterium tuberculosis virulence. Mol. Microbiol.41(1), 179–187 (2001).
   PubMed Web of Science ®Google Scholar
• Kamath AT, Fruth U, Brennan MJ et al. New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. Vaccine 23(29), 3753–3761 (2005).
   PubMed Web of Science ®Google Scholar
• Zahrt TC, Deretic V. An essential two-component signal transduction system in Mycobacterium tuberculosis. J. Bacteriol.182(13), 3832–3838 (2000).
   PubMed Web of Science ®Google Scholar
• Boom WH, Canaday DH, Fulton SA, Gehring AJ, Rojas RE, Torres M. Human immunity to M. tuberculosis: T-cell subsets and antigen processing. Tuberculosis83(1–3), 98–106 (2003).
   PubMed Web of Science ®Google Scholar
• Vergne I, Chua J, Singh SB, Deretic V. Cell biology of Mycobacterium tuberculosis phagosome. Ann. Rev. Cell. Dev. Biol. 20, 367–394 (2004).
   PubMed Web of Science ®Google Scholar
• Hess J, Miko D, Catic A, Lehmensiek V, Russell DG, Kaufmann SH. Mycobacterium bovis Bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proc. Natl Acad. Sci. USA 95(9), 5299–5304 (1998).
   PubMed Web of Science ®Google Scholar
• Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl Acad. Sci. USA 97(25), 13853–13858 (2000).
   PubMed Web of Science ®Google Scholar
• Williams A, Hatch GJ, Clark SO et al. Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis 85(1–2), 29–38 (2005).
   PubMed Web of Science ®Google Scholar
• Brodin P, Majlessi L, Brosch R et al. Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T-cell immunity against region of difference 1 antigens. J. Infect. Dis. 190(1), 115–122 (2004).
   PubMed Web of Science ®Google Scholar
• De Groot AS, Rappuoli R. Genome-derived vaccines. Expert Rev. Vaccines1, 59–76 (2004).
   PubMedGoogle Scholar
• Pizza M, Scarlato V, Masignani V et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287(5459), 1816–1820 (2000).
   PubMed Web of Science ®Google Scholar
• Capecchi B, Serruto D, Adu-Bobie J, Rappuoli R, Pizza M. The genome revolution in vaccine research. Curr. Issues Mol. Biol. 6(1), 17–27 (2004).
   PubMedGoogle Scholar